ProCE Banner Activity

Considerations for PrEP for People Who Inject Drugs

Clinical Thought
Adherence and accessibility are critical to improving uptake and effectiveness of PrEP for PWID.

Released: April 15, 2022

Expiration: April 14, 2023

Share

Faculty

Karine Lacombe

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, and MSD.